United States & United States — DARPA

United States: The United States>>> market, particularly its defense and advanced materials sectors, becomes a key focus for First Graphene Limited>>> following its acquisition of Mito Material Solutions>>>, enhancing access to significant revenue opportunities.

United States — DARPA: United States — DARPA>>> initiatives on graphene-enhanced materials align with the expanded capabilities of First Graphene Limited>>> after acquiring Mito Material Solutions>>>.

United States: The United States expanded an existing drone contract with Redwire by $15 million for Stalker surveillance UAVs, reinforcing its reliance on Redwire's defense technology.

United States — DARPA: United States — DARPA awarded Redwire a prime contract for the 'Otter' program to develop air-breathing spaceplanes, advancing research in very low Earth orbit operations.

United States: The United States government, through DARPA, is providing funding to Xanadu Quantum Technologies.

United States — DARPA: United States — DARPA (DARPA) is providing up to $15 million in funds to Xanadu Quantum Technologies through its Quantum Benchmarking Initiative program.

United States: The United States's Office of Naval Research, in partnership with the United States — DARPA, selected the USX-1 Defiant to evaluate Hyliion Holdings>>>'s KARNO Power Module>>> technology.

United States — DARPA: The United States — DARPA partnered with the United States's Office of Naval Research to select a test vessel for evaluating Hyliion Holdings>>>'s KARNO Power Module>>> technology.

United States: The United States government, through DARPA, is involved in evaluating quantum systems, and the Trump administration backed a Microsoft spin-out.

United States — DARPA: The United States — DARPA selected Microsoft as a participant in its Quantum Benchmarking Initiative, validating Microsoft's topological quantum architecture and its potential for utility-scale performance.

United States — DARPA: United States — DARPA (DARPA) has funded projects related to TMS and neuroplastic therapy, and Dr. McBride previously served as a Program Manager there, indicating potential future collaboration.